FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.)
Yosef
December 17, 2022
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.)
Below are links to eighteen publications describing clinical studies of ASPS with novel treatments as
We selected to highlight 3 studies that were presented this year at the ASCO conference:
An experimental drug, cediranib, may benefit alveolar soft part sarcoma (ASPS) patients, according a recent
For Alveolar Soft Part Sarcoms patients the use of aggressive surgery, appropriate diagnostic imaging, and long-term surveillance
Lung metastases affect a significant part of the ASPS patients at some point of their
Stereotactic Radiosurgery (SRS) is a medical procedure, which is non-invasive surgery to destroy tumors. High
Designed with ❤️ by Studio Luxmeo | Developed by Yoav Levavi